ALX Oncology (NASDAQ:ALXO) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of ALX Oncology (NASDAQ:ALXO) in a report issued on Thursday morning, Benzinga reports. The firm currently has a $25.00 price objective on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating on shares of ALX Oncology in a research report on Wednesday, May 29th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, ALX Oncology currently has an average rating of Moderate Buy and a consensus price target of $18.17.

ALX Oncology Stock Down 7.9 %

ALXO traded down $0.22 during trading hours on Thursday, hitting $2.58. The company’s stock had a trading volume of 307,386 shares, compared to its average volume of 757,719. ALX Oncology has a fifty-two week low of $2.55 and a fifty-two week high of $17.83. The company has a quick ratio of 5.21, a current ratio of 5.21 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $7.45 and a 200 day simple moving average of $11.92.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, May 9th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.16. As a group, equities research analysts expect that ALX Oncology will post -2.89 earnings per share for the current year.

Insider Transactions at ALX Oncology

In other news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $15.92, for a total transaction of $318,400.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company’s stock, valued at approximately $9,618,943.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $15.92, for a total value of $318,400.00. Following the completion of the sale, the insider now owns 604,205 shares of the company’s stock, valued at $9,618,943.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Peter S. Garcia bought 12,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was acquired at an average cost of $8.53 per share, with a total value of $102,360.00. Following the transaction, the chief financial officer now owns 122,348 shares of the company’s stock, valued at $1,043,628.44. The disclosure for this purchase can be found here. Insiders sold a total of 78,469 shares of company stock valued at $873,346 in the last three months. 33.40% of the stock is currently owned by corporate insiders.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently modified their holdings of ALXO. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ALX Oncology in the fourth quarter worth about $28,000. CANADA LIFE ASSURANCE Co bought a new position in shares of ALX Oncology in the first quarter worth about $27,000. EntryPoint Capital LLC bought a new position in shares of ALX Oncology in the first quarter worth about $32,000. China Universal Asset Management Co. Ltd. increased its stake in shares of ALX Oncology by 445.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after purchasing an additional 4,706 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after buying an additional 5,200 shares in the last quarter. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.